115 related articles for article (PubMed ID: 33841676)
1. Efficacy and safety of crizotinib plus bevacizumab in
Huang Z; Xiong Q; Cui Z; Tao H; Zhang S; Wang L; Cui P; Chen S; Huang D; Yang B; Hu Y
Am J Transl Res; 2021; 13(3):1526-1534. PubMed ID: 33841676
[TBL] [Abstract][Full Text] [Related]
2. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38280448
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K; Yoh K; Toyozawa R; Horinouchi H; Morise M; Ohashi K; Murakami H; Satouchi M; Sakakibara-Konishi J; Yano S; Okumura F; Matsumoto S; Shimokawa M; Seto T; Goto K
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38758397
[TBL] [Abstract][Full Text] [Related]
4. Real-life experience of ceritinib in crizotinib-pretreated
Cadranel J; Cortot AB; Lena H; Mennecier B; Do P; Dansin E; Mazieres J; Chouaid C; Perol M; Barlesi F; Robinet G; Friard S; Thiberville L; Audigier-Valette C; Vergnenegre A; Westeel V; Slimane K; Buturuga A; Moro-Sibilot D; Besse B
ERJ Open Res; 2018 Jan; 4(1):. PubMed ID: 29450203
[TBL] [Abstract][Full Text] [Related]
5. Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic
Huang Y; Zhang S; Hu X; Wang X; Zhao Y; Li Z
AME Case Rep; 2024; 8():38. PubMed ID: 38711893
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
Nadal E; Rifi N; Kane S; Mbacke S; Starkman L; Suero B; Le H; Samjoo IA
Lung Cancer; 2024 May; 192():107816. PubMed ID: 38749072
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of iruplinalkib (WX‑0593) on non‑small cell lung cancer with
Zhang Q; Lv J; Li X; Zhang H; Zhu C; Wang M; Si M; Hu Y; Zhang S
Exp Ther Med; 2024 Feb; 27(2):53. PubMed ID: 38234623
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of ensartinib-treated
Yuan X; Wang Y; Yang M; Wu P; Chen H; Yun Y; Shen Z; Ji D; Ma Y; Ding L
Lung Cancer Manag; 2023 Dec; 12(4):LMT61. PubMed ID: 38239813
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Trial of the MET/
Piha-Paul SA; Dumbrava EE; Nair BC; Xiong W; Xu L; Mostorino R; Subbiah V; Tannir N; Fu S; Naing A; Janku F; Karp DD; Patel S; Daw NC; Hong D; Meric-Bernstam F; Zinner R
Onco Targets Ther; 2021; 14():3037-3049. PubMed ID: 33994796
[TBL] [Abstract][Full Text] [Related]
10. Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations.
Wang Y; Xu M; Wang K; Hao Y; Xu C; Song Z
Ther Adv Med Oncol; 2024; 16():17588359241248352. PubMed ID: 38736555
[TBL] [Abstract][Full Text] [Related]
11. Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and
Dong SS; Dong W; Tan YF; Xiao Q; Wang TL
Front Oncol; 2024; 14():1370901. PubMed ID: 38690167
[TBL] [Abstract][Full Text] [Related]
12. Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC.
Pérol M
Transl Lung Cancer Res; 2014 Dec; 3(6):392-4. PubMed ID: 25806330
[No Abstract] [Full Text] [Related]
13. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Chuang CH; Chen HL; Chang HM; Tsai YC; Wu KL; Chen IH; Chen KC; Lee JY; Chang YC; Chen CL; Tu YK; Hung JY; Yang CJ; Chong IW
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921762
[TBL] [Abstract][Full Text] [Related]
16. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program.
Aparicio T; Cozic N; de la Fouchardière C; Meriaux E; Plaza J; Mineur L; Guimbaud R; Samalin E; Mary F; Lecomte T; Gomez-Roca C; Haineaux PA; Gratet A; Selves J; Menu Y; Colignon N; Johnson L; Legrand F; Vassal G
Target Oncol; 2021 May; 16(3):381-388. PubMed ID: 33847874
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Orlov SV; Iyevleva AG; Filippova EA; Lozhkina AM; Odintsova SV; Sokolova TN; Mitiushkina NV; Tiurin VI; Preobrazhenskaya EV; Romanko AA; Martianov AS; Ivantsov AO; Aleksakhina SN; Togo AV; Imyanitov EN
Transl Oncol; 2021 Aug; 14(8):101121. PubMed ID: 34030112
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
